Lantheus (LNTH) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed Alpha Teknova (TKNO) over the past year, gaining 93.2% versus a gain of 66.2%. Over five years, LNTH leads with a +330.7% price change compared with -62.3% for TKNO. Lantheus is the larger company by market cap ($6.54 billion vs $459.6 million), about 14.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | TKNO |
|---|---|---|
| Share price | $100.20 | $8.56 |
| Market cap | $6.54B | $459.57M |
| 1-day change | +0.01% | -1.72% |
| YTD return | +50.53% | +129.21% |
| 1-year return | +93.25% | +66.22% |
| 5-year return | +330.70% | -62.29% |
| P/E ratio (TTM) | 24.26 | — |
| Forward P/E | 15.71 | — |
| EPS (TTM) | $4.13 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | — |
| Revenue growth (YoY) | +0.50% | — |
| Net income (latest FY) | $233.56M | — |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | — |
| Net margin | 15.15% | — |
| 52-week high | $111.86 | $9.48 |
| 52-week low | $50.16 | $1.91 |
| Distance from 52-week high | -10.43% | -9.70% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +7.53% | +5.14% |
| Average volume | 1.32M | 230.99K |
| Shares outstanding | 65.30M | 53.69M |
| Employees | 1,193 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 14.2 times larger than Alpha Teknova by market value ($6.54B vs $459.57M).
- LNTH has outperformed TKNO by 27.0 percentage points over the past year.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
LNTH vs TKNO FAQ
Which is bigger, Lantheus or Alpha Teknova?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $459.57M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, LNTH or TKNO?
LNTH returned +93.25% over the past 12 months, compared with +66.22% for TKNO (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.